Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240013/S032

Affera Sphere-9 Mapping and Ablation Catheter

Medtronic, Inc. · Decision date Oct 9, 2026

MEDTECHLEDGER EXPLANATIONP240013/S032

What did the FDA decide?

The FDA lists PMA supplement P240013/S032 for the Affera Sphere-9 Mapping and Ablation Catheter, filed as a 30-Day Notice. The stated reason is a process change involving a manufacturer, sterilizer, packager, or supplier. The source statement identifies the affected item as "an alternative to batch testing for bacterial endotoxin testing (BET)," so the notice concerns endotoxin testing method rather than the catheter's ablation technology or clinical indication.

The identifier establishes this as a supplement to PMA P240013, not a new approval of the whole system. The notice covers a manufacturing change; it does not report data on safety or clinical effectiveness. The source also does not specify which supplier or facility is affected, the test method replacing batch testing, or any validation results, leaving those details absent.

FDA approval order statement

an alternative to batch testing for bacterial endotoxin testing (BET)
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 9, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240013/S032
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
OK30
Decision date
Oct 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240013 · Original PMA

    Sphere-9 Catheter and Affera Ablation System

  2. P240013/S032 received

    Application receipt date recorded by FDA.

  3. P240013/S031 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  4. P240013/S028 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  5. P240013/S032 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240013

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalOct 24, 2024FDA
Medtronic, Inc.PMA supplementOct 2, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records